The detection of the methylated Wif-1 gene is more accurate than a fecal occult blood test for colorectal cancer screening
Name:
Article-PLoS_ONE-The_detect-2014.pdf
Size:
289.0Kb
Format:
PDF
Description:
Article - Full Text
Name:
Supplement_1_-_PLoS_ONE-The_detect-2014.pone.0099233.s001.doc
Size:
316.5Kb
Format:
Microsoft Word
Description:
Supplemental File 1
Name:
Supplement_2_-_PLoS_ONE-The_detect-2014.pone.0099233.s002.docx
Size:
15.45Kb
Format:
Microsoft Word 2007
Description:
Supplemental File 2
Name:
Supplement_3_-_PLoS_ONE-The_detect-2014.pone.0099233.s003.docx
Size:
16.37Kb
Format:
Microsoft Word 2007
Description:
Supplemental File 3
Name:
Supplement_4_-_PLoS_ONE-The_detect-2014.pone.0099233.s004.doc
Size:
36.5Kb
Format:
Microsoft Word
Description:
Supplemental File 4
Type
ArticleAuthors
Amiot, AurelienMansour, Hicham
Baumgaertner, Isabelle
Delchier, Jean-Charles
Tournigand, Christophe
Furet, Jean-Pierre
Carrau, Jean-Pierre
Canoui-Poitrine, Florence
Sobhani, Iradj
KAUST Department
Bioscience Core LabDate
2014-07-15Permanent link to this record
http://hdl.handle.net/10754/334640
Metadata
Show full item recordAbstract
Background: The clinical benefit of guaiac fecal occult blood tests (FOBT) is now well established for colorectal cancer screening. Growing evidence has demonstrated that epigenetic modifications and fecal microbiota changes, also known as dysbiosis, are associated with CRC pathogenesis and might be used as surrogate markers of CRC. Patients and Methods: We performed a cross-sectional study that included all consecutive subjects that were referred (from 2003 to 2007) for screening colonoscopies. Prior to colonoscopy, effluents (fresh stools, sera-S and urine-U) were harvested and FOBTs performed. Methylation levels were measured in stools, S and U for 3 genes (Wif1, ALX-4, and Vimentin) selected from a panel of 63 genes; Kras mutations and seven dominant and subdominant bacterial populations in stools were quantified. Calibration was assessed with the Hosmer-Lemeshow chi-square, and discrimination was determined by calculating the C-statistic (Area Under Curve) and Net Reclassification Improvement index. Results: There were 247 individuals (mean age 60.8±12.4 years, 52% of males) in the study group, and 90 (36%) of these individuals were patients with advanced polyps or invasive adenocarcinomas. A multivariate model adjusted for age and FOBT led to a C-statistic of 0.83 [0.77-0.88]. After supplementary sequential (one-by-one) adjustment, Wif-1 methylation (S or U) and fecal microbiota dysbiosis led to increases of the C-statistic to 0.90 [0.84-0.94] (p = 0.02) and 0.81 [0.74-0.86] (p = 0.49), respectively. When adjusted jointly for FOBT and Wif-1 methylation or fecal microbiota dysbiosis, the increase of the C-statistic was even more significant (0.91 and 0.85, p<0.001 and p = 0.10, respectively). Conclusion: The detection of methylated Wif-1 in either S or U has a higher performance accuracy compared to guaiac FOBT for advanced colorectal neoplasia screening. Conversely, fecal microbiota dysbiosis detection was not more accurate. Blood and urine testing could be used in those individuals reluctant to undergo stool testing. © 2014 Amiot et al.Citation
Amiot A, Mansour H, Baumgaertner I, Delchier J-C, Tournigand C, et al. (2014) The Detection of the Methylated Wif-1 Gene Is More Accurate than a Fecal Occult Blood Test for Colorectal Cancer Screening. PLoS ONE 9: e99233. doi:10.1371/journal.pone.0099233.Publisher
Public Library of Science (PLoS)Journal
PLoS ONEPubMed ID
25025467PubMed Central ID
PMC4099003ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0099233
Scopus Count
Except where otherwise noted, this item's license is described as This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related articles
- Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer.
- Authors: Zhang H, Zhu YQ, Wu YQ, Zhang P, Qi J
- Issue date: 2014 May 28
- Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
- Authors: Medical Advisory Secretariat
- Issue date: 2009
- Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer.
- Authors: Roperch JP, Incitti R, Forbin S, Bard F, Mansour H, Mesli F, Baumgaertner I, Brunetti F, Sobhani I
- Issue date: 2013 Dec 1
- [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
- Authors: Quintero E
- Issue date: 2009 Oct
- Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
- Authors: van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E
- Issue date: 2008 Jul